Mangrove Partners’s Immunovant IMVT Stock Holding History

Mangrove Partners’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-222,400	Closed	-$1.23M	–	526
2022 Q1	$1.23M	Sell	222,400 -348,000	-61%	-$2.17M	0.07%	349
2021 Q4	$4.86M	Sell	570,400 -569,500	-50%	-$4.7M	0.29%	90
2021 Q3	$9.91M	Buy	1,139,900 +130,400	+13%	+$1.18M	0.89%	17
2021 Q2	$10.7M	Buy	+1,009,500	New	+$14.1M	1.1%	13

Other funds holding IMVT

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Mangrove Partners's IMVT Position: Q2 2022 in Review

Mangrove Partners sold out of Immunovant (IMVT) in Q2 2022, closing a stake of 368,000 shares — an estimated $2.03M sold.

Mangrove Partners first reported a position in IMVT in Q3 2019 and held it in 10 quarters. The position peaked at $8.9M in Q1 2020. 94 funds tracked by Wall St. Rank hold IMVT as of Q2 2022.

Mangrove Partners reported no remaining Immunovant position as of Q2 2022 after selling out during the quarter.
Mangrove Partners sold 368,000 Immunovant shares in Q2 2022, an estimated $2.03M.
Mangrove Partners first reported a position in Immunovant in Q3 2019 and held it in 10 quarters.
Mangrove Partners's Immunovant position peaked at $8.9M in Q1 2020.
94 funds tracked by Wall St. Rank held Immunovant as of Q2 2022.

Based on Mangrove Partners's 13F filing for Q2 2022, filed 15 Aug 2022.